Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,566 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Risk factors for tumor lysis syndrome in patients with chronic lymphocytic leukemia treated with the cyclin-dependent kinase inhibitor, flavopiridol.
Blum KA, Ruppert AS, Woyach JA, Jones JA, Andritsos L, Flynn JM, Rovin B, Villalona-Calero M, Ji J, Phelps M, Johnson AJ, Grever MR, Byrd JC. Blum KA, et al. Among authors: byrd jc. Leukemia. 2011 Sep;25(9):1444-51. doi: 10.1038/leu.2011.109. Epub 2011 May 24. Leukemia. 2011. PMID: 21606960 Free PMC article.
Longitudinal genome-wide analysis of patients with chronic lymphocytic leukemia reveals complex evolution of clonal architecture at disease progression and at the time of relapse.
Braggio E, Kay NE, VanWier S, Tschumper RC, Smoley S, Eckel-Passow JE, Sassoon T, Barrett M, Van Dyke DL, Byrd JC, Jelinek DF, Shanafelt TD, Fonseca R. Braggio E, et al. Among authors: byrd jc. Leukemia. 2012 Jul;26(7):1698-701. doi: 10.1038/leu.2012.14. Epub 2012 Jan 20. Leukemia. 2012. PMID: 22261920 Free PMC article. No abstract available.
Dinaciclib is a novel cyclin-dependent kinase inhibitor with significant clinical activity in relapsed and refractory chronic lymphocytic leukemia.
Flynn J, Jones J, Johnson AJ, Andritsos L, Maddocks K, Jaglowski S, Hessler J, Grever MR, Im E, Zhou H, Zhu Y, Zhang D, Small K, Bannerji R, Byrd JC. Flynn J, et al. Among authors: byrd jc. Leukemia. 2015 Jul;29(7):1524-9. doi: 10.1038/leu.2015.31. Epub 2015 Feb 24. Leukemia. 2015. PMID: 25708835 Free PMC article. Clinical Trial.
Leukemia-cell proliferation and disease progression in patients with early stage chronic lymphocytic leukemia.
Murphy EJ, Neuberg DS, Rassenti LZ, Hayes G, Redd R, Emson C, Li K, Brown JR, Wierda WG, Turner S, Greaves AW, Zent CS, Byrd JC, McConnel C, Barrientos J, Kay N, Hellerstein MK, Chiorazzi N, Kipps TJ, Rai KR. Murphy EJ, et al. Among authors: byrd jc. Leukemia. 2017 Jun;31(6):1348-1354. doi: 10.1038/leu.2017.34. Epub 2017 Jan 24. Leukemia. 2017. PMID: 28115735 Free PMC article.
Extended follow-up and impact of high-risk prognostic factors from the phase 3 RESONATE study in patients with previously treated CLL/SLL.
Brown JR, Hillmen P, O'Brien S, Barrientos JC, Reddy NM, Coutre SE, Tam CS, Mulligan SP, Jaeger U, Barr PM, Furman RR, Kipps TJ, Cymbalista F, Thornton P, Caligaris-Cappio F, Delgado J, Montillo M, DeVos S, Moreno C, Pagel JM, Munir T, Burger JA, Chung D, Lin J, Gau L, Chang B, Cole G, Hsu E, James DF, Byrd JC. Brown JR, et al. Among authors: byrd jc. Leukemia. 2018 Jan;32(1):83-91. doi: 10.1038/leu.2017.175. Epub 2017 Jun 8. Leukemia. 2018. PMID: 28592889 Free PMC article. Clinical Trial.
1,566 results